Share on StockTwits

Intersect ENT’s (NASDAQ:XENT) quiet period is set to expire on Tuesday, September 2nd. Intersect ENT had issued 5,000,000 shares in its initial public offering on July 24th, Stock Ratings Network.com reports. The total size of the offering was $55,000,000 based on an initial share price of $11.00. During the company’s quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

A number of research firms have recently commented on XENT. Analysts at Wedbush initiated coverage on shares of Intersect ENT in a research note on Monday, August 18th. They set an “outperform” rating and a $18.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. initiated coverage on shares of Intersect ENT in a research note on Monday, August 18th. They set an “overweight” rating and a $22.00 price target on the stock. Finally, analysts at Leerink Swann initiated coverage on shares of Intersect ENT in a research note on Monday, August 18th. They set an “outperform” rating and a $20.00 price target on the stock.

Intersect ENT (NASDAQ:XENT) traded up 2.60% during mid-day trading on Monday, hitting $16.20. 53,740 shares of the company’s stock traded hands. Intersect ENT has a 52-week low of $12.02 and a 52-week high of $16.93. The stock has a 50-day moving average of $14.27 and a 200-day moving average of $14.27. The company’s market cap is $364.5 million.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.